We are live on !
Find out more
Cliff Asness AQR Capital Management
AUM
$287B
Turnover
8.35%
1-Year Est. Return
42.33%
Cliff Asness is a co-founder of AQR Capital Management, a leading quantitative investment firm spanning equities, alternatives, and factor strategies. He is known for academic-informed research on value, momentum, and other systematic premia, as well as candid market commentary. Asness’s work bridges academic finance and large-scale institutional portfolio management.
This Fund
S&P 500
This Quarter Est. Return
+22.95%
1 Year Est. Return
+42.33%
3 Year Est. Return
+119.89%
5 Year Est. Return
+147.33%
10 Year Est. Return
+543.74%
AUM
$287B
AUM Growth
+$68.5B
(+31%)
Cap. Flow
+$37.5B
Cap. Flow % of AUM
Cap. Flow %
13.08%
Top 10 Holdings %
Top 10 Hldgs %
12.15%
Holding
3,986
New
247
Increased
2,455
Reduced
1,098
Closed
86
Avg Time Held
4.1
years
Top 10 Avg Time Held
3.3
years
Top 20 Avg Time Held
2.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$1.17B |
| 2 |
Apple
AAPL
|
+$849M |
| 3 |
Chevron
CVX
|
+$746M |
| 4 |
Synopsys
SNPS
|
+$643M |
| 5 |
Wells Fargo
WFC
|
+$633M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Micron Technology
MU
|
+$517M |
| 2 |
Booking.com
BKNG
|
+$488M |
| 3 |
Walmart Inc
WMT
|
+$414M |
| 4 |
Sandisk
SNDK
|
+$355M |
| 5 |
Cigna
CI
|
+$325M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.5% |
| 2 | Financials | 14.38% |
| 3 | Industrials | 14.2% |
| 4 | Consumer Discretionary | 10.53% |
| 5 | Healthcare | 10.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1651
Veracyte
VCYT
$4.14B
| $8.79M | ﹤0.01% |
149,648
+59,326
| +66% | +$2.49M |
2022 Q4
14 quarters
|
|
1652
Gladstone Commercial Corp
GOOD
$548M
| $8.79M | ﹤0.01% |
714,482
+266,923
| +60% | +$3.33M |
2020 Q3
23 quarters
|
|
1653
Apogee Enterprises
APOG
$953M
| $8.79M | ﹤0.01% |
192,089
+104,406
| +119% | +$3.9M |
2019 Q3
27 quarters
|
|
1654
Indivior Pharmaceuticals
INDV
$4.09B
| $8.77M | ﹤0.01% |
213,851
-90,351
| -30% | -$3.28M |
2025 Q3
3 quarters
|
|
1655
Absci
ABSI
$2.08B
| $8.77M | ﹤0.01% |
756,541
+57,102
| +8% | +$322K |
2024 Q3
7 quarters
|
|
1656
Honda
HMC
$43.9B
| $8.74M | ﹤0.01% |
322,214
+187,712
| +140% | +$4.77M |
2024 Q1
9 quarters
|
|
1657
Emergent Biosolutions
EBS
$366M
| $8.72M | ﹤0.01% |
1,041,151
+51,474
| +5% | +$431K |
2025 Q3
3 quarters
|
|
1658
Usana Health Sciences
USNA
$267M
| $8.71M | ﹤0.01% |
408,086
+111,666
| +38% | +$2.1M |
2013 Q2
52 quarters
|
|
1659
Skydance Corporation
SKYD
$39.5B
| $8.69M | ﹤0.01% |
890,177
+206,895
| +30% | +$2.18M |
2025 Q3
3 quarters
|
|
1660
Arcutis Biotherapeutics
ARQT
$3.99B
| $8.66M | ﹤0.01% |
330,324
-137,929
| -29% | -$3.21M |
2023 Q4
10 quarters
|
|
1661
Century Aluminum
CENX
$3.43B
| $8.66M | ﹤0.01% |
188,232
+21,999
| +13% | +$1.32M |
2024 Q1
9 quarters
|
|
1662
Kosmos Energy
KOS
$1.61B
| $8.63M | ﹤0.01% |
4,087,736
+2,795,495
| +216% | +$7.78M |
2019 Q1
29 quarters
|
|
1663
MillerKnoll
MLKN
$1.47B
| $8.61M | ﹤0.01% |
425,311
+21,401
| +5% | +$343K |
2013 Q2
52 quarters
|
|
1664
Astec Industries
ASTE
$918M
| $8.61M | ﹤0.01% |
140,674
+31,923
| +29% | +$1.76M |
2025 Q1
5 quarters
|
|
1665
Ducommun
DCO
$2.55B
| $8.59M | ﹤0.01% |
46,354
-1,585
| -3% | -$235K |
2022 Q1
17 quarters
|
|
1666
TETRA Technologies
TTI
$885M
| $8.58M | ﹤0.01% |
757,701
+6,293
| +0.8% | +$61.7K |
2021 Q2
20 quarters
|
|
1667
W&T Offshore
WTI
$610M
| $8.57M | ﹤0.01% |
2,720,068
+1,980,998
| +268% | +$7.35M |
2024 Q3
7 quarters
|
|
1668
Vanguard 0-3 Month Treasury Bill ETF
VBIL
$11.4B
| $8.55M | ﹤0.01% |
112,943
-74,024
| -40% | -$5.59M |
2025 Q3
3 quarters
|
|
1669
Cogent Communications
CCOI
$397M
| $8.54M | ﹤0.01% |
615,561
+405,652
| +193% | +$7.48M |
2025 Q1
5 quarters
|
|
1670
Unitil
UTL
$1B
| $8.53M | ﹤0.01% |
161,858
+130,703
| +420% | +$6.78M |
2024 Q2
8 quarters
|
|
1671
Thryv Holdings
THRY
$55.1M
| $8.51M | ﹤0.01% |
2,159,331
+935,980
| +77% | +$3.33M |
2022 Q1
17 quarters
|
|
1672
Novavax
NVAX
$1.71B
| $8.5M | ﹤0.01% |
902,650
+790,593
| +706% | +$7.08M |
2024 Q3
7 quarters
|
|
1673
Madrigal Pharmaceuticals
MDGL
$9.9B
| $8.5M | ﹤0.01% |
15,827
-126
| -0.8% | -$64.5K |
2022 Q4
14 quarters
|
|
1674
York Water
YORW
$499M
| $8.5M | ﹤0.01% |
277,196
+159,506
| +136% | +$4.79M |
2025 Q2
4 quarters
|
|
1675
Wise Group
WSE
$10.6B
| $8.49M | ﹤0.01% |
+708,379
| New | +$8.45M |
2026 Q2
0 quarters
|
|
Similar funds
Cliff Asness's Q2 2026 Portfolio in Review
As of Q2 2026, Cliff Asness held 3,986 positions worth $287B, up 31% from $218B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Cliff Asness deployed $37.5B of net new capital in Q2 2026, opening 247 new positions and adding to 2,455 existing holdings. Its largest new stake was FedEx Freight: 1,024,555 shares worth $155M.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 22% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Micron Technology, an estimated $517M trimmed.
- Cliff Asness's largest Q2 2026 buy was FedEx Freight: 1,024,555 shares worth $155M.
- Cliff Asness added most to NVIDIA in Q2 2026, an estimated $1.17B increase.
- Cliff Asness's biggest Q2 2026 reduction was Micron Technology, cutting an estimated $517M.
- Cliff Asness fully exited Masimo in Q2 2026, selling an estimated $147M.
- Cliff Asness's ten largest holdings make up 12% of its $287B portfolio in Q2 2026.
- Cliff Asness opened 247 new positions and closed 86 in Q2 2026.
- Cliff Asness's portfolio value rose 31% quarter-over-quarter to $287B.
Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.